Lv1
42 积分 2023-04-11 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
3天前
已完结
Focal adhesion kinase inhibitors as maintenance therapy in a homologous recombination repair proficient high-grade serous ovarian cancer murine model
7天前
已关闭
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer
7天前
已完结
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study
1个月前
已完结
Ceritinib overcomes proteasome inhibitor resistance in multiple myeloma by suppressing the protein folding response
3个月前
已关闭
Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response
4个月前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
4个月前
已完结
Use of Plasma and Brain Unbound Fractions to Assess the Extent of Brain Distribution of 34 Drugs: Comparison of Unbound Concentration Ratios to in Vivo P-Glycoprotein Efflux Ratios
6个月前
已完结
Antibody–Bottlebrush Conjugates Unlock Diverse Payloads for Targeted Cancer Therapy
7个月前
已完结
Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors
8个月前
已完结
皖公网安备34019202002308
